GlassScriptPhysician profile
James Blair Steier
NPI 1255402798
$2,054.65
in general payments reported to CMS, 2019-2025
17 companies · $664 in 2025
The $664 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.94 · 2020: $424 · 2021: $332 · 2022: $303 · 2023: $223 · 2024: $95.15 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $691.25 | 2020-2025 | Tavneos, Otezla, Enbrel |
| Abbvie INC. | $311.10 | 2020-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $251.03 | 2021-2025 | Saphnelo |
| Pfizer INC. | $216.82 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $102.31 | 2025 | |
| Glaxosmithkline, LLC. | $90.56 | 2021-2025 | Benlysta |
| Ucb, INC. | $86.47 | 2021-2024 | Cimzia |
| Organon LLC | $71.23 | 2023-2025 | Hadlima, Renflexis |
| Sandoz INC. | $55.04 | 2024-2025 | Hyrimoz, Jubbonti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.79 | 2021-2024 | Cyltezo |
| Genzyme Corporation | $26.56 | 2025 | |
| Depuy Synthes Sales INC. | $24.48 | 2025 | Monovisc, Orthovisc |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Sumitomo Pharma America, INC. | $18.17 | 2024 | Gemtesa |
| Fresenius Kabi USA, LLC | $16.77 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $15.44 | 2025 | Tremfya |
| Dexcom, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Steier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.